Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Nowadays the association between radiotherapy and the anti- Epidermal Growth Factor Receptor
(anti-EGFR) monoclonal antibody Cetuximab represents a valid option in the treatment of head
and neck locally advanced squamous neoplasm and, particularly, of oropharynx carcinoma. Up to
date we have only indirect comparison with the standard curative treatment (i.e. concurrent
radiochemotherapy) and the preliminary data show equivalent efficacy of both regimens. For
this reason, concurrent Cetuximab and radiotherapy is administered in patients not eligible
to chemoradiotherapy. The introduction of Cetuximab has been associated to new kind of
toxicities, especially cutaneous, that have increasingly reported.
The aim of our study is to improve the toxicity/benefit ratio in patients receiving
concurrent radiotherapy and cetuximab for locally advanced head and neck neoplasm. Hence,
this improvement could be achieved by modulating radiation therapy dose per fraction
following Cetuximab pharmacokinetics.